drugset / Trial / NCT01598064

Probiotics for Liver Cirrhosis With Portal Hypertension

NCT01598064 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Recent studies indicate that probiotics can stimulate intestinal immunity and tighten the junctions of epithelial cells. By these ways, probiotics can reduce bacterial translocation; hence, they can ameliorate systemic inflammatory status. Because cirrhotic patients with portal hypertension often suffer from infections from intestinal flora, the investigators speculate that probiotics will be beneficial to those patients.

Timeline

Start
2012-04
Primary completion
2013-08
Completion
2013-08

Outcome

Missed primary endpoint

registry analysis (superiority or other test); GK#10 vs Placebo; p = 0.25; Chi-squared NCT01598064 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject GK#10 Unknown 1 unknown —